MediPharm Labs Appoints New Chief Fiscal Officer

TORONTO, Jan. 29, 2021 (World NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ)…

TORONTO, Jan. 29, 2021 (World NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a world leader in specialised, research-driven pharmaceutical-excellent hashish extraction, distillation and spinoff products, is happy to announce Greg Hunter will sign up for MediPharm Labs as Chief Fiscal Officer (CFO), helpful February 8, 2021.

Greg Hunter delivers more than 20 yrs of knowledge as a small business executive keeping various senior finance and leadership roles across numerous industries which includes healthcare distribution, telecommunications, prescription drugs, biotechnology, health care unit and client packaged items. Greg also provides a monitor report and deep know-how in money administration, audit, compliance, tax, treasury, ERP, producing, deal management and pricing tactic.

“As MediPharm continues to emphasis on accelerating the expansion and execution of our worldwide pharmaceutical, wellbeing and wellness small business, Greg’s track record in expanding significant pharmaceutical functions mixed with a track report in strategic capital allocation and value management is a strong addition to our Corporation,” mentioned Keith Strachan, President and Interim CEO, MediPharm Labs. “As we search to seize new advancement possibilities and increase our merchandise offerings, his addition will assure that we are perfectly positioned to execute on our ideas and provide worthwhile development in the long term.”

Most just lately, Greg was Chief Monetary Officer of Health-related Pharmacies Team Minimal, a major pharmacy and clinical devices manufacturer and distributor in Canada. Previously in the pharmaceuticals field, Greg held numerous senior management roles with Baxter International Inc. together with serving as CFO of Baxter’s Canadian subsidiary. Greg also earlier held many senior operational and finance roles at Janssen-Ortho Inc., a Johnson and Johnson firm.

Keith Strachan added, “I would also like to thank Olga Utkutug for her a lot of contributions and management as Interim CFO. We look forward to her ongoing guidance as a critical member of our finance workforce.”

Greg retains an MBA from McMaster College, an Honors B.Sc. in Microbiology and Immunology from College of Western Ontario and is a Chartered Qualified Accountant.

In link with Greg’s appointment as CFO, the Enterprise granted 600,000 inventory options to him with an exercising selling price set at the near of organization on January 28, 2021. Every grant has a 5-year term expiring January 28, 2026, and vests in five equivalent instalments, the very first of which vests quickly with the 4 other instalments vesting on the dates which are 6, twelve, eighteen and 20-four months from the grant day. The stock solutions are topic to any necessary regulatory approvals.

About MediPharm Labs Corp.

Started in 2015, MediPharm Labs specializes in the generation of purified, pharmaceutical high quality hashish oil and concentrates and superior spinoff merchandise using a Great Producing Tactics licensed facility with ISO standard constructed clean up rooms. MediPharm Labs has invested in an expert, exploration-pushed workforce, condition-of-the-artwork technological innovation, downstream purification methodologies and purpose-constructed amenities with 5 primary extraction lines for shipping and delivery of pure, reliable and precision -dosed hashish items for its shoppers. By way of its wholesale and white label platforms, they formulate, customer-examination, process, bundle and distribute cannabis extracts and highly developed cannabinoid-based products and solutions to domestic and worldwide markets. As a world leader, MediPharm Labs has accomplished business exports to Australia and has thoroughly commercialized its wholly-owned Australian extraction facility. MediPharm Labs Australia was founded in 2017.

CAUTIONARY Notice Pertaining to Forward-Looking Information:

This information release has “forward-searching information” and “forward-seeking statements” (collectively, “forward-looking statements”) inside the indicating of the applicable Canadian securities legislation. All statements, other than statements of historic simple fact, are ahead-on the lookout statements and are primarily based on anticipations, estimates and projections as at the date of this information release. Any statement that involves conversations with regard to predictions, expectations, beliefs, programs, projections, goals, assumptions, future activities or general performance (usually but not normally using phrases this kind of as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variants of these terms and phrases or stating that certain actions, activities or outcomes “may” or “could”, “would”, “might” or “will” be taken to manifest or be attained) are not statements of historical actuality and may perhaps be forward-on the lookout statements. In this information launch, forward-on the lookout statements relate to, among other issues, statements about: accelerating the expansion and execution of the Company’s world-wide pharmaceutical, wellbeing and wellness small business new progress chances expanded product or service offerings and executing on programs and delivering worthwhile progress in the future. Ahead-wanting statements are always based mostly on a range of estimates and assumptions that, whilst thought of fair, are subject to recognized and not known risks, uncertainties, and other things which could result in the true results and long run functions to vary materially from these expressed or implied by these types of forward-on the lookout statements. This sort of variables include things like, but are not confined to: normal business, economic, aggressive, political and social uncertainties the incapability of MediPharm Labs to acquire adequate funding the hold off or failure to receive regulatory approvals and other aspects mentioned in MediPharm Labs’ filings, offered on the SEDAR web page at www.sedar.com. There can be no assurance that such statements will confirm to be precise, as actual effects and foreseeable future situations could vary materially from individuals anticipated in these types of statements. Accordingly, audience really should not place undue reliance on the ahead-hunting statements and information and facts contained in this news launch. Except as essential by law, MediPharm Labs assumes no obligation to update the ahead-hunting statements of beliefs, thoughts, projections, or other factors, should they transform.

For even more information, be sure to contact: Laura Lepore, VP, Trader Relations Phone: 705-719-7425 ext 1525 Email: [email protected] Web-site: www.medipharmlabs.com